A RETROSPECTIVE COMPARATIVE STUDY ON THE OUTCOME OF CASIRIVIMAB -IMDEVIMAB ANTIBODY COCKTAIL TREATMENT IN COVID-19 PATIENTS

Dr. Reshma T. S. PHARM D., Dr. Praise Mariam Abraham PHARM D., Dr. Swetha Joju MBBS, *Dr. Hari Lakshmanan P. MD, Dr. Siby Joseph PhD, Dr. Muhammed Jasim Abdul Jalal DNB, Dr. Mohammed Iqbal MBBS, MRCP UK, FRCP(London), FRCP(Edin), FRCP(Glasgow), Dr. Joseph K. Joseph MD

ABSTRACT

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus which causes respiratory illness. Monoclonal antibodies have been widely used as a prophylaxis or treatment for managing this viral infection. Our research aims to compare the outcome of covid patients who were treated with and without Antibody Cocktail therapy. This will help physicians to get an insight into antibody cocktail therapy in covid patients in the Indian population.The research shows that antibody cocktail treatment is associated with faster remission of covid symptoms and provides up to 3 months of covid free interval in the Indian population. But it is indifferent to the development of post covid symptoms However the severity is found to be less in the test group compared to the control group.

Keywords: Covid 19, Antibody Cocktail Therapy, Regen Cov.